Seven-month kinetics of SARS-CoV-2 antibodies and protective role of pre-existing antibodies to seasonal human coronaviruses on COVID-19

Unraveling the long-term kinetics of antibodies to SARS-CoV-2 and the individual characteristics influencing it, including the impact of pre-existing antibodies to human coronaviruses causing common cold (HCoVs), is essential to understand protective immunity to COVID-19 and devise effective surveil...

Descripción completa

Detalles Bibliográficos
Autores: Ortega, Natalia, Ribes, Marta, Vidal, Marta, Rubio, Rocío, Aguilar, Ruth, Williams, Sarah, Barrios, Diana, Alonso, Selena, Hernández-Luis, Pablo, Mitchell, Robert A., Jairoce, Chenjerai, Cruz, Angeline, Jiménez, Alfons, Santano, Rebeca, Méndez, Susana, Lamoglia Puig, Montserrat, Rosell, Neus, Llupià García, Anna, Puyol, Laura, Chi, Jordi, Rodrigo-Melero, Natalia, Parras, Daniel, Serra, Pau, Pradenas Saavedra, Edwards, Trinité, Benjamin, Blanco, Julià, Mayor Aparicio, Alfredo Gabriel, Barroso, Sonia, Varela, Pilar, Vilella, Anna, Trilla Garcia, Antonio De Padua, Santamaria, Pere, Carolis, Carlo, Tortajada, Marta, Izquierdo Lázaro, Luis, Angulo Aguado, Ana, Engel Rocamora, Pablo, Garcia-Basteiro, Alberto L, Moncunill Piñas, Gemma, Dobaño, Carlota, 1969-
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/225440
Acceso en línea:https://hdl.handle.net/2445/225440
Access Level:acceso abierto
Palabra clave:SARS-CoV-2
Pandèmia de COVID-19, 2020-2023
COVID-19 Pandemic, 2020- 2023
Descripción
Sumario:Unraveling the long-term kinetics of antibodies to SARS-CoV-2 and the individual characteristics influencing it, including the impact of pre-existing antibodies to human coronaviruses causing common cold (HCoVs), is essential to understand protective immunity to COVID-19 and devise effective surveillance strategies. IgM, IgA and IgG levels against six SARS-CoV-2 antigens and the nucleocapsid antigen of the four HCoV (229E, NL63, OC43 and HKU1) were quantified by Luminex, and antibody neutralization capacity was assessed by flow cytometry, in a cohort of health care workers followed up to 7 months (N = 578). Seroprevalence increases over time from 13.5% (month 0) and 15.6% (month 1) to 16.4% (month 6). Levels of antibodies, including those with neutralizing capacity, are stable over time, except IgG to nucleocapsid antigen and IgM levels that wane. After the peak response, anti-spike antibody levels increase from ~150 days post-symptom onset in all individuals (73% for IgG), in the absence of any evidence of re-exposure. IgG and IgA to HCoV are significantly higher in asymptomatic than symptomatic seropositive individuals. Thus, pre-existing cross-reactive HCoVs antibodies could have a protective effect against SARS-CoV-2 infection and COVID-19 disease.

Similares en LA Referencia